Aprotinin (3000KIU) + Fibrinogen (70mg) + Thrombin (500IU)

Clinical Pharmacologist's Monograph

⚠️ Prescription Only: This medicine is Schedule H/H1. Do not self-medicate.

1. Clinical Overview

A topical hemostatic agent, also known as a fibrin sealant or tissue adhesive, combining bovine-derived aprotinin, human-derived fibrinogen, and bovine-derived thrombin. It mimics the final stage of the coagulation cascade, forming a stable fibrin clot at the site of application. Primarily used in surgical settings to control bleeding where conventional methods are ineffective or impractical.

OnsetDurationBioavailability
Within 30-60 seconds of application.The fibrin clot is stable for 10-14 days before being degraded by fibrinolysis.Not applicable (Topical application). Systemic absorption is minimal and not relevant for therapeutic effect.

2. Mechanism of Action

The combination mimics the final step of the coagulation cascade. Thrombin (Factor IIa) enzymatically cleaves fibrinogen to form fibrin monomers. These monomers spontaneously polymerize to form a fibrin mesh. Factor XIII (present in plasma and often in the fibrinogen component) is activated by thrombin to cross-link the fibrin polymer, forming a stable, insoluble clot. Aprotinin, a serine protease inhibitor, acts as an antifibrinolytic agent by inhibiting plasmin and kallikrein, thereby protecting the newly formed fibrin clot from premature degradation.

3. Indications & Uses

  • Hemostasis in surgery where control of bleeding by conventional surgical techniques is ineffective or impractical (e.g., cardiovascular surgery, liver surgery, splenic trauma).
  • Sealing of colonic anastomoses to prevent leakage.
  • As an adjunct in skin grafting for fixation of grafts (e.g., mesh grafts).
  • Sealing of cerebrospinal fluid leaks in neurosurgery.

4. Dosage & Administration

Adult Dosage: Dosage is not fixed; it depends on the size of the area to be treated. The standard vial composition (3000 KIU Aprotinin + 70mg Fibrinogen + 500 IU Thrombin) is typically sufficient for an area of 4-6 cm². Apply the minimum volume required to achieve hemostasis.

Administration: Supplied as a dual-chamber syringe or separate vials. The fibrinogen/aprotinin solution and thrombin solution are mixed at the time of application using a provided applicator tip. Apply as a thin layer using a spatula, spray, or drip technique directly onto the bleeding surface. Hold in place with gentle pressure for 1-3 minutes. Must be used immediately after reconstitution/mixing.

5. Side Effects

Common side effects may include:

  • Local inflammatory reaction at application site.
  • Mild fever.

6. Drug Interactions

DrugEffectSeverity
Antifibrinolytic agents (e.g., Tranexamic acid, Aminocaproic acid)Additive antifibrinolytic effect. Risk of excessive thrombosis if systemic absorption occurs.Moderate
Anticoagulants (e.g., Heparin, Warfarin)May reduce the local hemostatic efficacy of the sealant. Systemic anticoagulation overrides local effect.Major
Anti-platelet drugs (e.g., Aspirin, Clopidogrel)May reduce the efficacy of the fibrin clot by impairing platelet plug integration.Moderate

7. Patient Counselling

  • Inform your surgeon about any known allergies, especially to beef or bovine products.
  • Disclose all medications, especially blood thinners.
  • Understand that this is a surgical aid applied by the doctor, not a take-home medication.

8. Toxicology & Storage

Overdose: Topical overdose is unlikely. Theoretical risks from massive application include systemic absorption leading to: nausea, hypotension, tachycardia, allergic reactions, and potential for thromboembolism.

Storage: Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Keep in outer carton. The reconstituted/mixed product must be used immediately and cannot be stored. Check expiry date before use.